On Friday’s Options Action on CNBC we got a question from a viewer about whether or not it was two late to buy puts in Valeant (VRX)? Well, this is obviously a pretty complicated case, …
Continue readingVRX
Earlier, Dan previewed Adobe’s (ADBE) Q1 earnings due after the bell. Like I did last week with ORCL and ratio spreads versus long stock, I want to use ADBE’s earnings event as an educational look into another …
Continue reading
Bill Ackman, founder of hedge fund firm Pershing Square, might have dropped out of the three comas club in the last week with his 21.5 million share position in Valeant (VRX) down about 25% from last week’s …
Continue reading
In August, fears of systemic financial risk briefly roiled our equity markets. That was the first time those fears had bubbled up since 2011. Since then, central banks globally have at least talked the talk …
Continue reading
This morning, hedge fund heavyweight and founder of Pershing Square Bill Ackman is holding a call with investors and the financial press to answer questions about his nearly $2 billion stake in specialty pharmaceuticals company Valeant …
Continue reading
This Valeant (VRX) story is far from done. For those that thought the volatility in the stock was brought on solely by some shadowy short biased research house, think again. The WSJ set its sites on …
Continue reading
Despite the weakness in the broader stock market to start 2014, the CBOE put/call ratio has remained below 1 for every session since October 15th. That’s the longest such streak since late 2001/2002 (the real …
Continue reading